Corcept Therapeutics (CORT) Tops Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. SPY
10. FISV

Go back to Corcept Therapeutics (CORT) Tops Q4 EPS by 3c

Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

February 8, 2021 4:05 PM EST

Financial Highlights, 2021 Revenue Guidance and Legal Update

Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 20192021 revenue guidance $375 - 405 millionPreliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share in fourth quarter 2019Preliminary cash and investments at December 31, 2020 of $476.9 million, an increase of $161.6 million from December 31, 2019Patent Trial and Appeals Board... More